Abstract
Rapid tumour progression in neuroblastoma is associated with MYCN amplification, deletion of the short arm of chromosome 1 and gain of 17q. However, patients with advanced disease without MYCN amplification and/or 1p deletion have a very poor outcome too, which suggests other genetic defects may predict an unfavourable prognosis. We employed CGH to study 22 tumours of patients at stages 3 and 4 over one year of age (6 and 16 cases respectively). Patients were divided in groups (A) long-term survivors and (B) short-term survivors. CGH showed a total of 226 chromosome imbalances (110 in group A and 116 in group B). The neuroblastoma cells of long-term survivors showed a preponderance of numerical aberrations (54% vs 43%); particularly gains of entire chromosomes 1 (P < 0.03), 7 (P < 0.04) and 19 (P < 0.05). An extra copy of 17 was detected in 6/8 (75%) samples of group A and only 1/14 (7%) samples of group B (P < 0.002). Conversely, tumours of patients who died from disease progression displayed a higher frequency of structural abnormalities (43% vs 35%), including loss of 1p, 9p, 11q, 15q and 18q and gain of 12q, although the difference was not significant (P = 0.24). Unbalanced gain of 17q was detected in 8/14 (57%) tumours of group B and only 1/8 (13%) tumours of group A (P < 0.05). The peculiar genetic difference observed in the tumours of long and short-term survivors may have prognostic relevance. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Amler LC, Schurmann J and Schwab M (1996) The DDXI gene maps within 400 kbp 5′ to MYCN and is frequently coamplified in human neuroblastoma. Genes, Chromosom & Cancer 15: 134–137
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Boecker W, Lampert F and Stoerkel S (1997) Comparative genomic hybridization (CGH) analysis of neuroblastomas – an important methodological approach in paediatric tumour pathology. J Pathol 181: 394–400
Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson ADJ, Plantaz D, Meddeb M, Danglot G, Brinkschidt C, Christiansen H, Laureys G and Speleman F (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340: 1954–1961
Brodeur GM, Pritchard J, Berthold F, Carlsen NTL, Castel V, Castleberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y and Vaute PA (1993) Revision of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11: 1466–1477
Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA and Versteeg R (1996) Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 25: 225–230
George RE, Kenyon AG, McGuckin AG, Kohl N, Kogner P, Christiansen H, Pearson ADJ and Lunec J (1997) Analysis of candidate gene co-amplified with MYCN in neuroblastoma. Eur J Cancer 12: 2037–2042
Iolascon A, Giordani L, Tonini GP, Lo Cunsolo C, Mastropietro S, Borriello A and della Ragione F (1998) Differential expression of cyclin dependent kinase inhibitor genes (CDKN2A, CDKN2B) in human neuroblastoma: significant correlation between CDKN2B expression and advanced stage III and IV. Pediatric Res 43: 139–144
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 30: 818–821
Lastowska M, Nacheva E, McGuckin A, Curtis A, Grace C, Pearson ADJ and Bown N (1997) Comparative genomic hybridization study of primary neuroblastoma tumors. Genes Chromosom Cancer 18: 162–169
Lastowska M, Van Roy N, Bown N, Speleman F, Lunec J, Strachan T, Pearson ADJ and Jackson MS (1998) Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cells lines. Genes Chromosom Cancer 23: 116–122
Lo Cunsolo C, Iolascon A, Cavazzana A, Cusano R, Strigini P, Mazzocco K, Giordani L, Massimo L, De Bernardi B, Conte M and Tonini GP (1999) Neuroblastoma in two siblings supports the role of chromosome 1p36 in tumor development. Cancer Genet and Cytogenet 109: 126–130
Meddeb M, Danglot G, Chudoba I, Venuat AM, Benard J, Avet-Loiseau H, Vasseur B, Le Paslier D, Terrier-Lacombe MJ, Hartmann O and Bernheim, (1996) Additional copies of a 25 Mb chromosomal region originating from 17q23.1–17 qter are present in 90% of high-grade neuroblastomas. Genes Chromosom Cancer 17: 156–165
Perri P, Pession A, Mazzocco K, Strigini P, Iolascon A, Basso G and Tonini GP (1996) Peculiar allelotype associated with susceptibility to neuroblastoma. Genes Chromosom Cancer 17: 60–63
Peter M, Michon J, Vielh P, Neuenschwander S, Nakamura Y, Sonsino E, Zucker JM, Vergnaud G, Thomas G and Delattre O (1992) PCR assay for chromosome 1p deletion in small neuroblastoma samples. Int J Cancer 52: 544–548
Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC and Feuerstein BG (1997) Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 50: 81–89
Seeger RC, Brodeur GM, Sather H, Dalton A, Siege SE, Wong KY and Hammond D (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111–1116
Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, Marsden HB and Misugi K (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73: 405–416
Takita J, Hayashi Y, Kohno T, Shiseki M, Yamaguchi N, Hanada R, Yamamoto K and Yokata J (1995) Allelotype of neuroblastoma. Oncogene 11: 1829–1834
Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Pession A, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P and De Bernardi B (1997) MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s. The Italian experience with 295 children. J Clin Oncol 15: 85–93
Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, Devalck C, Schuuring E, Brock P, Otten J, Gyselinck J, De Paepe A and Speleman F (1998) Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosom Cancer 23: 141–152
Van Gele M, Van Roy N, Jauch A, Laureys G, Benoit Y, Schelfhout V, De Potter CR, Brock P, Uyttebroeck A, Sciot R, Schuuring E, Versteeg R and Speleman F (1997) Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis. Eur J Cancer 33: 1979–1982
Van Roy N, Laureys G, Van Gele M, Opdenakker G, Miura R, van der Drift P, Chan A, Versteeg R and Speleman F (1997) Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes. Eur J Cancer 33: 1974–1978
Wimmer K, Zhu XX, Lamb BJ, Kuick R, Ambros PF, Kovar H, Thoraval D, Motyka S, Alberts, JR and Hanash SM (1999) Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. Oncogene 18: 233–238
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cunsolo, C., Bicocchi, M., Petti, A. et al. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status. Br J Cancer 83, 1295–1300 (2000). https://doi.org/10.1054/bjoc.2000.1432
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1432
Keywords
This article is cited by
-
Weak linkage at 4p16 to predisposition for human neuroblastoma
Oncogene (2002)